ATE517637T1 - Elektroporation von mycobacterium und überexpression von antigenen in mycobacteria - Google Patents

Elektroporation von mycobacterium und überexpression von antigenen in mycobacteria

Info

Publication number
ATE517637T1
ATE517637T1 AT05852317T AT05852317T ATE517637T1 AT E517637 T1 ATE517637 T1 AT E517637T1 AT 05852317 T AT05852317 T AT 05852317T AT 05852317 T AT05852317 T AT 05852317T AT E517637 T1 ATE517637 T1 AT E517637T1
Authority
AT
Austria
Prior art keywords
mycobacteria
mycobacterium
overexpression
electroporation
antigens
Prior art date
Application number
AT05852317T
Other languages
English (en)
Inventor
Ronggai Sun
David Hone
Jerald Sadoff
Original Assignee
Aeras Global Tuberculosis Vaccine Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeras Global Tuberculosis Vaccine Foundation filed Critical Aeras Global Tuberculosis Vaccine Foundation
Application granted granted Critical
Publication of ATE517637T1 publication Critical patent/ATE517637T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05852317T 2004-12-01 2005-11-29 Elektroporation von mycobacterium und überexpression von antigenen in mycobacteria ATE517637T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63197704P 2004-12-01 2004-12-01
PCT/US2005/042976 WO2006060332A2 (en) 2004-12-01 2005-11-29 Electroporation of mycobacterium and overexpression of antigens in mycobacteria

Publications (1)

Publication Number Publication Date
ATE517637T1 true ATE517637T1 (de) 2011-08-15

Family

ID=36565595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05852317T ATE517637T1 (de) 2004-12-01 2005-11-29 Elektroporation von mycobacterium und überexpression von antigenen in mycobacteria

Country Status (16)

Country Link
US (1) US7625572B2 (de)
EP (1) EP1817061B1 (de)
JP (1) JP5461776B2 (de)
KR (1) KR101382215B1 (de)
CN (1) CN101076356B (de)
AP (1) AP2869A (de)
AT (1) ATE517637T1 (de)
AU (1) AU2005312062B2 (de)
BR (1) BRPI0518080A (de)
CA (1) CA2587507C (de)
DK (1) DK1817061T3 (de)
EA (1) EA012182B1 (de)
ES (1) ES2370885T3 (de)
MX (1) MX2007006552A (de)
WO (1) WO2006060332A2 (de)
ZA (1) ZA200704764B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047286A1 (en) * 2004-12-01 2010-02-25 Aeras Global Tb Vaccine Foundation Recombinant BCG strains with enhanced ability to escape the endosome
US7829104B2 (en) * 2004-12-01 2010-11-09 Aeras Global Tb Vaccine Foundation Electroporation of Mycobacterium and overexpression of antigens in mycobacteria
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8852916B2 (en) * 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
EP1962910A4 (de) * 2005-12-15 2010-03-31 Aeras Global Tb Vaccine Found Neuartige prime-boost-kombination aus abgeschwächten mycobakterien
WO2009045575A2 (en) * 2007-06-14 2009-04-09 The Regents Of The University Of California Unmarked recombinant intracellular pathogen immunogenic compositions expressing high levels of recombinant proteins
CA2867516A1 (en) * 2012-04-02 2013-10-10 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
EP2838990A4 (de) 2012-04-16 2016-08-10 Aeras Global Tb Vaccine Found Rekombinantes mycobakterium zur codierung eines heparin-bindenden hämagglutinin (hbha)-fusionsproteins und verwendungen davon
US11712777B2 (en) * 2019-06-10 2023-08-01 Rohm And Haas Electronic Materials Cmp Holdings, Inc. Cationic fluoropolymer composite polishing pad
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN118221791B (zh) * 2024-05-23 2024-08-23 山东第二医科大学 一种Rv0653c蛋白、其抗体及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736367A (en) * 1992-03-31 1998-04-07 Medimmune, Inc. Vectors and prokaryotes which autocatalytically delete antibiotic resistance
US5783386A (en) * 1994-02-24 1998-07-21 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Mycobacteria virulence factors and a novel method for their identification
KR100217809B1 (ko) * 1994-07-29 1999-09-01 슈도 야마자키 재조합 bcg 백신
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US6004815A (en) * 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
US6562348B2 (en) * 1999-07-08 2003-05-13 Albert Einstein College Of Medicine Of Yeshiva University Recombinant M. tuberculosis auxotrophic for leucine and vaccines using same
US6423545B1 (en) * 1999-07-08 2002-07-23 Albert Einstein College Of Medicine Of Yeshiva University Unmarked deletion mutants of mycobacteria and methods of using same
CN1342771A (zh) * 2001-09-17 2002-04-03 复旦大学 结核分枝杆菌Ag85B抗原的表达纯化和作为疫苗组份的应用
BRPI0606165A2 (pt) * 2005-01-05 2009-06-02 Isis Innovation método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada

Also Published As

Publication number Publication date
JP5461776B2 (ja) 2014-04-02
EA200701130A1 (ru) 2007-12-28
CN101076356B (zh) 2013-04-03
WO2006060332A2 (en) 2006-06-08
US20060121054A1 (en) 2006-06-08
MX2007006552A (es) 2007-08-20
BRPI0518080A (pt) 2008-10-28
EA012182B1 (ru) 2009-08-28
CA2587507A1 (en) 2006-06-08
DK1817061T3 (da) 2011-11-14
EP1817061A4 (de) 2009-07-08
ES2370885T3 (es) 2011-12-23
CN101076356A (zh) 2007-11-21
KR101382215B1 (ko) 2014-04-08
JP2008521435A (ja) 2008-06-26
EP1817061A2 (de) 2007-08-15
CA2587507C (en) 2013-11-19
AP2007004021A0 (en) 2007-06-30
ZA200704764B (en) 2008-09-25
US7625572B2 (en) 2009-12-01
AU2005312062B2 (en) 2011-11-17
KR20070111452A (ko) 2007-11-21
WO2006060332A3 (en) 2006-08-03
AU2005312062A1 (en) 2006-06-08
AP2869A (en) 2014-03-31
EP1817061B1 (de) 2011-07-27

Similar Documents

Publication Publication Date Title
ATE517637T1 (de) Elektroporation von mycobacterium und überexpression von antigenen in mycobacteria
IL183458A0 (en) Anti-il-1r1 single domain antibodies and therapeutic uses
IL178593A (en) Specific antibodies of fcγriib and methods for their use
DK3589081T3 (da) Effektstyringfremgangsmåder og -apparat
KR101528970B9 (ko) 항체의 농축 방법 및 이의 치료용 생성물
EP1804843A4 (de) Adhäsive nahtstruktur und anwendungsverfahren dafür
ATE542648T1 (de) Rasierer und kassetten
DE602005019084D1 (de) Rasierer und kassetten
BRPI0821658A2 (pt) Anticorpos contra nkg2d humano e usos dos mesmos
IL182734A0 (en) 4-aminotetracyclines and methods of use thereof
ZA200805741B (en) Anti-MN antibodies and methods of using same
PT1784419E (pt) Domínios e epitopos da proteína meningocócica nmb1870
EP1746902A4 (de) Multilektin-affiniätschromatografie und verwendung dafür
ZA200704908B (en) IL-15 Antigen Arrays and uses thereof
IL186342A0 (en) Spirocyclic heterocycic derivaives and methods of their use
EP1703943A4 (de) Verfahren, gerät und geladene chemikalien zur kontrolle von ionen, molekülen oder elektronen
DE112005002192A5 (de) Kraftauswertevorrichtung und Kraftauswerteverfahren zur Bestimmung von Gleichgewichtskenngrössen
EP1794589A4 (de) Protein-arrays und verfahren zu ihrer verwendung
DE602006016688D1 (de) Schiebendes und schwingendes tragbares Endgerät
DE602004007850D1 (de) Authentifizierungsverfahren und -vorrichtung
EP1838288A4 (de) Therapeutische stoffe und verfahren
EP1784209A4 (de) Kontrazeptiva auf basis von sp22 und sp22-antikörpern
DE602006019849D1 (de) Proteinspaltungsverfahren und verwendung davon
DE602005012674D1 (de) Nachweiselement und nachweisverfahren
DE602006006710D1 (de) Herstellung von polytrimethylenetherglykol und copolymeren davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties